Last $74.97 USD
Change Today +0.28 / 0.37%
Volume 2.3M
BAX On Other Exchanges
Symbol
Exchange
New York
Berlin
SIX Swiss Ex
Mexico
As of 4:15 PM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

baxter international inc (BAX) Snapshot

Open
$74.66
Previous Close
$74.69
Day High
$75.48
Day Low
$74.38
52 Week High
07/23/14 - $77.31
52 Week Low
10/2/13 - $62.80
Market Cap
40.6B
Average Volume 10 Days
2.3M
EPS TTM
$4.86
Shares Outstanding
541.7M
EX-Date
09/3/14
P/E TM
15.4x
Dividend
$2.08
Dividend Yield
2.65%
Current Stock Chart for BAXTER INTERNATIONAL INC (BAX)

baxter international inc (BAX) Related Businessweek News

View More BusinessWeek News

baxter international inc (BAX) Details

Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney diseases, trauma, and other chronic and acute medical conditions. Its BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and certain vaccines. The company’s Medical Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics; products and services related to pharmacy compounding, drug formulation, and packaging technologies; and technologies and therapies for peritoneal dialysis, in-center and home hemodialysis, and continuous renal replacement therapy. It sells its products through its direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers to hospitals, kidney dialysis and rehabilitation centers, nursing homes, doctors’ offices, clinical and medical research laboratories, and patients. The company has collaboration with Cell Therapeutics, Inc. to develop and commercialize pacritinib; Coherus Biosciences, Inc. and Momenta Pharmaceuticals, Inc. to develop and commercialize biosimilars; JW Holdings Corporation for parenteral nutritional products containing a formulation of omega 3 lipids; Onconova Therapeutics, Inc. for rigosertib, an anti-cancer compound; and Chatham Therapeutics, LLC to develop and commercialize product for the treatments of hemophilia B. It operates in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Latin America, and Canada. The company was founded in 1931 and is based in Deerfield, Illinois.

61,000 Employees
Last Reported Date: 02/21/14
Founded in 1931

baxter international inc (BAX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer and Corporate Vice Pr...
Total Annual Compensation: $687.7K
Corporate Vice President and President of Int...
Total Annual Compensation: $771.2K
Corporate Vice President and President of Bio...
Total Annual Compensation: $742.3K
Compensation as of Fiscal Year 2013.

baxter international inc (BAX) Key Developments

Baxter International Inc. Declares Quarterly Dividend Payable on October 1, 2014

The Board of Directors of Baxter International Inc. declared a quarterly dividend of $0.52 per Baxter common share. The dividend is payable on October 1, 2014 to shareholders of record as of September 5, 2014. In May, Baxter increased its dividend by 6%, bringing the annual dividend rate to $2.08 per diluted share and maintaining a dividend payout ratio of approximately 40%.

Baxter International Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Third Quarter of 2014 and Revises Earnings Guidance for the Full Year of 2014

Baxter International Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. The company posted net income of $520 million and earnings per diluted share of $0.95 in the second quarter, compared to net income of $590 million and earnings per diluted share of $1.07 in the same period last year. On an adjusted basis, excluding special items in both periods, the company’s second quarter net income of $692 million increased 5% from $659 million reported in 2013. Adjusted earnings per diluted share of $1.26 also increased 5% from $1.20 per diluted share last year. Net sales were $4,264 million against $3,669 million a year ago. Pre-tax income was $661 million against $743 million a year ago. Adjusted pre-tax income was $885 million against $844 million a year ago. Cash flows from operations were $599 million against $763 million for the same period a year ago. Capital expenditures were $423 million against $347 million for the same period a year ago. For the six months of 2014, the company reported net income of $1.1 billion, or $1.96 per diluted share, compared to net income of $1.1 billion and earnings per diluted share of $2.07 reported in 2013. Excluding special items, the company’s adjusted net income increased 7% to $1,344 million against $1,260 million a year ago. Adjusted earnings per diluted share of $2.45 also increased 7% from $2.29 per diluted share reported in the comparable prior-year period. Net sales were $8,215 million against $7,117 million a year ago. Pre-tax income was $1,370 million against $1,436 million a year ago. Adjusted pre-tax income was $1,714 million against $1,607 million a year ago. Cash flows from operations were $1,158 million against $1,149 million for the same period a year ago. Capital expenditures were $844 million against $639 million for the same period a year ago. Net debt as on June 30, 2014 was $6,973 million against $3,046 million a year ago. For the third quarter of 2014, the company expects sales growth of approximately 12% to 13% excluding the impact of foreign currency. The company expects earnings, before special items, of $1.28 to $1.32 per diluted share in the third quarter. The third quarter 2014 earnings guidance excludes approximately $0.07 per diluted share of projected intangible asset amortization expense. For the full year 2014, the company now expects sales growth of 10% to 11% before the impact of foreign exchange. Also for the full year, the company expects earnings, before special items, of $5.10 to $5.20 per diluted share and cash flows from operations of approximately $3.5 billion, excluding cash costs related to the spin-off of the biopharmaceutical business. The full-year 2014 earnings guidance excludes the $0.62 per diluted share of special items comprising $0.49 per diluted share of items recorded in the first half of the year, and projected intangible asset amortization expense of $0.13 per diluted share for the remainder of the year. Reconciling for the inclusion of these items results in GAAP earnings of $4.48 to $4.58 per diluted share for the full-year 2014. The company expects interest expense to total approximately $160 million and the company now expect other income of approximately $70 million for the full year, the vast majority of which has already been recognized in the first half of the year. The company expects the tax rate of approximately 21.5%. From a cash flow perspective, the company continue to expect to generate cash flow from operations of approximately $3.5 billion, which excludes the cash cost associated with the spin off of the biopharmaceuticals business. The company expects capital expenditures of approximately $1.8 billion, which includes Gambro and the investments the company is making to enhance plasma manufacturing footprint in Covington, Georgia. As mentined previously, the company expects earnings per diluted share, excluding special items, of $1.28 to $1.32. The company expects sales growth, excluding the impact of foreign currency, of 12% to 13%. Excluding Gambro, the company expects the base Baxter sales at constant currency rates to grow approximately 4% to 5%. For the full year, the company continue to expect gross margin for the company to decline by approximately 150 basis points from the 2013 margin of 52%.

Baxter Launches Romanian Subsidiary

Baxter has opened a subsidiary in Romania, with an office in the capital, Bucharest, staffed by 12 people who will be responsible for sales, marketing, and regulatory activities, reports Central Europe Pharma News. Baxter has only worked with distributors in the country, rather than having any dedicated representation. Tomov has reportedly estimated that the company's revenue in Romania would reach USD 10 million in 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAX:US $74.97 USD +0.28

BAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,398 JPY -17.00
Covidien PLC $86.93 USD +0.42
Danone SA €53.99 EUR -0.10
Kimberly-Clark Corp $104.90 USD +1.03
Takeda Pharmaceutical Co Ltd ¥4,700 JPY -27.00
View Industry Companies
 

Industry Analysis

BAX

Industry Average

Valuation BAX Industry Range
Price/Earnings 21.0x
Price/Sales 2.5x
Price/Book 4.7x
Price/Cash Flow 20.8x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAXTER INTERNATIONAL INC, please visit www.baxter.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.